Fig. 2From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET studyProgression-free survival (PFS). PFS is shown for patients treated with mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab). A log-rank test did not reveal any significant differences in PFS between the two groups (P = 0.99)Back to article page